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Abstract
Background: The ability to selectively detect and target cancer cells that have undergone an epithelial-mesenchymal
transition (EMT) may lead to improved methods to treat cancers such as pancreatic cancer. The remodeling of cellular
glycosylation previously has been associated with cell differentiation and may represent a valuable class of molecular
targets for EMT.
Methodology/Principal Findings: As a first step toward investigating the nature of glycosylation alterations in EMT, we
characterized the expression of glycan-related genes in three in-vitro model systems that each represented a
complementary aspect of pancreatic cancer EMT. These models included: 1) TGFb-induced EMT, which provided a look
at the active transition between states; 2) a panel of 22 pancreatic cancer cell lines, which represented terminal
differentiation states of either epithelial-like or mesenchymal-like; and 3) actively-migrating and stationary cells, which
provided a look at the mechanism of migration. We analyzed expression data from a list of 587 genes involved in
glycosylation (biosynthesis, sugar transport, glycan-binding, etc.) or EMT. Glycogenes were altered at a higher prevalence
than all other genes in the first two models (p,0.05 and ,0.005, respectively) but not in the migration model. Several
functional themes were shared between the induced-EMT model and the cell line panel, including alterations to matrix
components and proteoglycans, the sulfation of glycosaminoglycans; mannose receptor family members; initiation of O-
glycosylation; and certain forms of sialylation. Protein-level changes were confirmed by Western blot for the mannose
receptor MRC2 and the O-glycosylation enzyme GALNT3, and cell-surface sulfation changes were confirmed using Alcian
Blue staining.
Conclusions/Significance: Alterations to glycogenes are a major component of cancer EMT and are characterized by
changes to matrix components, the sulfation of GAGs, mannose receptors, O-glycosylation, and specific sialylated
structures. These results provide leads for targeting aggressive and drug resistant forms of pancreatic cancer cells.
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Introduction
Pancreatic cancer has one of the poorest survival rates of any
major cancer [1]. The extreme lethality of pancreatic cancer is
related to its tendency to disseminate at early stages prior to
diagnosis [2,3] and its resistance to chemotherapeutics [2,4]. The
acquisition of migratory and drug-resistant traits in pancreatic
cancer cells may occur in a step-by-step fashion, accompanied by
increasing changes to the genetics and morphologies of the cancer
cells. Early-stage and pre-malignant states are thought to consist of
dysplastic cells within pancreatic ducts [5], and the progression to
ductal adenocarcinoma is characterized by proliferating epithelial
cancer cells assembled in tube-like ductal structures surrounded by
fibrotic stroma. The metastatic dissemination of pancreatic cancer
requires cells to break away from the epithelial ductal structures
and take on characteristics of migratory, mesenchymal cells. This
transition involves enormous remodeling of the cell and is likely
driven by genetic aberrations, extracellular signals, and the
activation of differentiation programs in the cancer cells.
Characterizing the molecular alterations associated with the
phenotypic switch in pancreatic cancer cells from epithelial-like
to mesenchymal-like traits will provide insights into avenues for
detecting and targeting this conversion.
This major phenotypic switch in pancreatic cancer cells may be
driven by the epithelial-mesenchymal transition (EMT). EMT is a
biological program that coordinates the conversion of cell
PLoS ONE | www.plosone.org 1 September 2010 | Volume 5 | Issue 9 | e13002differentiation from the epithelial characteristics of strong cell-cell
adhesion, polarity, and smooth morphology to the mesenchymal
characteristics of minimal cell-cell contacts, loss of polarity, and
increased cell projections [2,6,7,8,9]. The EMT is normally
activated in development and wound healing during tissue
remodeling, but it is thought to be abnormally activated by
certain types of cancer cells to confer the traits associated with
highly lethal cancers. Multiple lines of evidence support the
importance of EMT in promoting pancreatic cancer aggressive-
ness. The general histological loss of cellular differentiation is a
highly accurate predictor of poor outcome in pancreatic cancer
[10,11], and the specific EMT markers of reduced E-cadherin and
increased vimentin correlate with poor survival [12,13] and
invasion [14]. Mouse models of pancreatic cancer recapitulate that
relationship [15]. In agreement with those findings, the induction
of a transcription factor called snail, which controls E-cadherin
repression, results in increased metastasis and chemoresistance of
pancreatic cancer cells [16]. Furthermore, the mesenchymal-like
cancer cells may be more drug-resistant than their epithelial-like
counterparts, as suggested by the correlation between Gemcita-
bine-resistance and mesenchymal traits [17] and the loss of EGFR-
inhibitor sensitivity in pancreatic cancer cells that have lost
epithelial-like traits [8]. Intensive investigations have uncovered
many of the regulatory mechanisms and molecular characteristics
of this conversion [2,6,7,8,9], but the in-vivo factors at work in
cancer EMT and that are relevant to pancreatic cancer
progression are not clear.
The glycosylation of a cancer cell may be significantly
remodeled during EMT, although the nature of this association
has not been well characterized. Glycosylation is a dynamic
process involving a concerted interplay between various glycosyl-
transferases and associated enzymes in the endoplasmic reticulum
and Golgi apparatus [18]. Glycan structures are involved in
proper protein folding [19,20,21], intracellular trafficking
[18,20,22], cell growth and differentiation, [20,23], adhesion and
migration [18,24], and cell-based immunity [20,25], among other
functions. Changes in glycans have been detected and implicated
in various pathologic conditions [23,26]. In addition, the
carbohydrate structures on cell-surface and secreted proteins are
good indicators of cell type and status, as they specifically change
in association with development [27,28], cell differentiation and
activation [29,30], and transformation [31]. Therefore we
hypothesized that pancreatic cancer EMT is characterized by
specific glycosylation alterations that play functional roles in
cancer cell differentiation or migration.
As an initial step in testing this hypothesis, we examined the
expression of glycosylation-related genes in three model systems of
EMT or migration. Monitoring gene expression is experimentally
more tractable than comprehensively characterizing glycan
structures associated with each model system, and we therefore
chose this route for an initial investigation. While it is not possible
to deduce glycan structures simply from gene expression of
glycogenes, expression alterations in glycogenes provide insights
on major structural alterations as well as leads on target points for
therapeutic intervention. Expression alterations in glycogenes
previously have been examined using focused microarrays or
PCR arrays designed to specifically measure the relevant
transcripts [32,33,34]. Here we demonstrate the use of whole-
genome expression profiling to capture the same information by
selectively analyzing data from a target gene list of 587 glycan-
associated genes (including genes relevant to EMT). An advantage
of this approach is the ability to use standard expression profiling
platforms as well as historical data that was not generated
specifically to examine glycogenes. We used cell culture systems in
which EMT could be controlled by stimulation with TGFb (model
1) or in which the terminal differentiation state of a variety of cell
lines could be classified as either epithelial-like or mesenchymal-
like (model 2). In addition, we examined gene expression patterns
in cells that were either actively migrating or stationary (model 3).
Each model system represents a different aspect of cell behavior
relating to EMT: active transition between states, terminal
differentiation states, or the activity of migration. We report here
the major alterations to glycan-associated gene expression that are
associated with each of the model systems and that are common
between the model systems.
Results
Glycogene expression in TGFb-induced EMT
The first model system in which we examined glycogene
expression changes was TGFb induction of EMT in the cell lines
Panc-1 and A549. The A549 cell line was not derived from
pancreatic cancer but was included to provide information about
the generality of the associations with EMT. In addition, by
looking for genes that change in both cell lines, we reduced the list
of candidate genes. TGFb treatment resulted in dissolution of cell-
cell adhesion and increases in spindle-like projections in both cells
lines (Figure S1). Whole-genome expression measurements were
obtained for the treated and untreated cells using Affymetrix gene
chips. For a focused analysis on genes of interest, we used our list
of 587 genes related to glycosylation and EMT-associated
pathways (see Table S1).
We first examined whether glycosylation-related genes showed a
higher rate of expression changes than all other genes (Table 1),
which may indicate a prominent role for glycosylation alterations
in EMT. Among all genes, 1,524 unique Affymetrix targets
changed expression in both Panc-1 and A549 after treatment with
TGFb. Since our glycan related genes represented 1.5% of the
total unique Affymetrix U133 Plus 2.0 targets, random represen-
tation of glycogenes predicts a corresponding 1.5% representation
of glycogenes (or 23 genes) among those that changed expression.
However, 40 of the 1,524 genes (2.6%) were glycogenes from our
target list. This difference was significant by chi-square analysis
(X
2=13.05, p,0.05). This result suggested an enrichment of
transcriptional regulation of glycan-related genes in TGFb-
induced EMT.
An examination of the genes that were altered more than 1.5-
fold in both cell lines (Tables 2 and 3) revealed some functional
themes. The greatest change was in the proteoglycan SPOCK1,
which contains glycosaminoglycan side chains of heparin- and
chondroitin-sulfate [35]. Related to this protein, genes that modify
glycosaminoglycan sulfation were up-regulated, including SULF2,
CHST3, and CHST11, and HAS2 was up-regulated, which is
involved in the synthesis of the glycosaminoglycan hyaluronan. A
lectin-like receptor involved in cell motility and extracellular
matrix remodeling, MRC2, was upregulated. Alterations to the
initiation of O-glycosylation were indicated by GALNT2 and
GALNT10 changes, and matrix adhesion changes were repre-
sented by the upregulation of several integrins and the matrix
protein LAMC2 (gamma 2 laminin). Other elevated genes
represent EMT and TGF signaling functions. The six genes with
reduced expression showed no particular enrichment in specificity,
with ST8SIA4 being the only reduced glycosyltransferase.
Glycogene Expression in a Pancreatic Cancer Cell Line
Panel
Thesecond modelsystemwas a panelof22pancreaticcancercell
lines. A diversity of cell morphologies and adhesion behaviors was
Glycogenes in EMT
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strong epithelial characteristics (rounded morphologies and numer-
ous cell-cell contacts) while others are clearly mesenchymal-like
(spindle-like projections and few cell-cell adhesions). Therefore we
sought to identify gene expression characteristics that differentiate
these two behaviors. This comparison does not directly address
EMT, but rather gives insights into the terminal differentiation
states associated with the mesenchymal and epithelial phenotypes.
We initially classified the cell lines as either epithelial-like or
mesenchymal-like based on morphology and clustering (Figure 1).
Cell lines such as CAPAN-2, HPAF-II, and BXPC-3 have dense,
rounded colonies and were unambiguously classified as epithelial-
like. On the other end of the spectrum MiaPaCa-2 and MPanc-96
clearly showed the mesenchymal characteristics of low cell-cell
interactions and spindle like cellular projections. Other cell lines
were more difficult to classify by these characteristics, showing
mixed or partial characteristics of each type. We therefore looked
at the expression of EMT-related genes as a means of classification
(Figure S2). Among those genes (see Figure S2 for the complete
list) the ZEB1 transcription factor most clearly corresponded to
Table 1. Rate of glycogene expression alterations.
Model System
Induced EMT
1 Cell line panel
2 Migrating cells
3
Total genes probed 35,888 35,888 16,087
Glycogenes probed (% of total) 555 (1.5%) 555 (1.5%) 525 (3.3%)
Total genes changing 1524 3675 2778
Glycogenes changing (% of total changing) 40 (2.6%) 87 (2.4%) 84 (3.0%)
Glycogene enrichment (p value, Chi-squared) p,0.05 p,0.005 Not significant
1Changed genes defined as significant (p,0.05) difference in the triplicate Panc-1 cells and +/20.25 fold change in the A549 cells.
2Changed genes defined as p,0.05 between mesenchymal-like and epithelial-like cell lines.
3Changed genes defined as +/20.25 fold change in both Panc-1 and MiaPaCa cells.
doi:10.1371/journal.pone.0013002.t001
Table 2. Genes with increased expression in TGFb-induced EMT.
Category Symbol Name
1
Entrez
ID
EMT Induced Panc-1 Fold
Change
2
EMT Induced A549
Fold Change
2
Glycoproteins SPOCK1 sparc/osteonectin, cwcv and kazal-like domains proteoglycan
(testican) 1
6695 8.04 70.53
TGFa ˆ Pathway LTBP2 latent transforming growth factor beta binding protein 2 4053 10.33 9.42
Glycan
Degradation
SULF2 sulfatase 2 55959 2.84 9.23
EMT Marker ZEB1 zinc finger E-box binding homeobox 1 6935 8.31 2.74
Glycoproteins LAMC2 laminin, gamma 2 3918 2.92 6.45
Notch pathway JAG1 jagged 1 precursor 182 5.54 3.10
Glycoproteins ITGA2 integrin, alpha 2 (CD49B, alpha 2 subunit of VLA-2 receptor) 3673 3.24 5.13
Glycan-transferase CHST3 carbohydrate (chondroitin 6) sulfotransferase 3 9469 2.31 4.30
TGFa ˆ Pathway TGFB1I1 transforming growth factor beta 1 induced transcript 1 7041 1.82 4.78
Glycoproteins ITGB3 integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61) 3690 3.84 2.58
Glycan-transferase HAS2 hyaluronan synthase 2 3037 1.50 4.87
Glycan-transferase CHST11 carbohydrate (chondroitin 4) sulfotransferase 11 50515 1.60 4.62
Glycoproteins ITGA5 integrin, alpha 5 (fibronectin receptor, alpha polypeptide) 3678 1.70 3.74
TGFa ˆ Pathway TGFB1 transforming growth factor, beta 1 7040 2.61 2.57
Glycan-transferase GALNT2 polypeptide N-acetylgalactosaminyltransferase 2 2590 2.35 2.78
Glycan-transferase GALNT10 ppGalNAc T10; GalNAc transferase 10 55568 2.19 2.64
EMT Marker ELK3 ETS-domain protein (SRF accessory protein 2) 2004 1.81 2.99
Nuc. Sugar SLC35F2 solute carrier family 35 member F2 54733 1.83 2.74
Glycoproteins ITGAV integrin, alpha V (vitronectin receptor, alpha polypeptide,
antigen CD51)
3685 1.58 2.68
CBP:C-Type Lectin MRC2 endocytic receptor (macrophage mannose receptor family) 2
mannose receptor, C type 2
9902 1.98 2.15
Glycoproteins ITGA3 integrin, alpha 3 (antigen CD49C, alpha 3 subunit of VLA-3
receptor)
3675 2.08 1.90
doi:10.1371/journal.pone.0013002.t002
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epithelial marker, E-cadherin (CDH-1) [6,7,8,9] in the mesenchy-
mal-like cells. A striking dichotomy of cells that were negative or
positive for ZEB1 was evident, dividing the cell lines into six that
were mesenchymal-like and 16 that were epithelial like. Based on
this classification, the expression of E-cadherin (CDH-1) was
significantly up regulated (p#0.01) and the expression of vimentin
(VIM) was significantly down regulated (p#0.01) in the epithelial
cells. The protein expression pattern of these two genes was
confirmed by Western blot (Figure 2). Therefore we used this
classification in subsequent analyses.
We examined whether glycan-related genes were different
between the groups at a higher rate than all other genes (Table 1).
Strictly by chance, since our glycan related genes represented 1.5%
of the total unique Affymetrix U133 Plus 2.0 targets, we expected a
corresponding 1.5% representation of glycogenes among the list of
total changing genes. However, of the 3,675 probes that showed
significantly altered levels of expression (p#0.05) between the
mesenchymal-like cells and the epithelial-like cells, 87 (2.37%) were
glycogenes from our target list. A chi-square analysis showed these
results to be highly significant (X
2=18.9, p#0.005). This trend
continued at higher levels of significance as 1212 unique Affymetrix
targets showed significantly different expression levels (p#0.01). Of
those targets, 30 (2.48%) were on our list as glycogenes, also a
significant difference by Chi-square analysis (X
2=8.12; p#0.005).
This analysis suggested an enrichment of transcriptional regulation
of glycan-related genes in the differentiation of cells between
mesenchymal and epithelial phenotypes.
The gene expression alterations for this model system are
summarized in Tables 4 and 5. Similar to above, a proteoglycan
was the most significantly overexpressed in the mesenchymal-like
cells, in this case VCAN (versican), and genes regulating the
sulfation of glycosaminoglycans were up-regulated, including
SULF2, CHST7, SGSH, and NDST2. Matrix modification was
also represented by upregulation of VIM (vimentin) and LAMA4
(alpha 4 laminin). Unlike in the induced-EMT model, genes
involved in branching or extending glycan chains were up-
regulated in the mesenchymal-like cells, including MGAT5B,
ST3GAL2, ST6GALNAC4, POMGNT1, and B3GNT1. The
mesenchymal-like cells also showed a striking down-regulation in
some genes, most notably GALNT3, which initiates O-glycosyl-
ation. GALNT3 was down-regulated in all six mesenchymal-like
cells, with an average decrease of ,1000-fold. Two C-type lectins
also were down-regulated, LY75 and CLEC3A. The expression
patterns of these genes clearly distinguish the mesenchymal-like
cell lines from the epithelial-like (Figure 3).
Glycogene expression in migrating and stationary
pancreatic cancer cells
The third model system was a comparison of actively migrating
cells to stationary cells [36]. Panc-1 and MiaPaCa-2 cells were
seeded as 1 mm defined circumference and cells were allowed to
migrate for 48 h. Two distinct morphological populations were
observed. The cells on the periphery of the cell cluster migrated
away from the region of high cell density (rim) and took on a
classical mesenchymal phenotype with spindle like projections and
loss of cell to cell adhesion. Cells that remained in the highly
populated center (core) showed greater intercellular adhesion and
were more rounded in appearance. The cells were harvested into
‘‘rim’’ and ‘‘core’’ groups by selectively collecting from each of
these two groups.
2,778 unique targets changed expression at least +/20.25-fold
in both the migrating MiaPaCa-2 and Panc-1 when compared to
their stationary counterparts (Table 1). Since our glycan-related
genes represented 3.0% of the total unique Agilent Whole Human
Genome Microarray Kit (4644K probes), random chance
predicted a corresponding 3.0% representation of glycogenes
among the list of genes that changed. That level of representation
was indeed observed, as 84 of the 2778 genes (3.0%) with altered
levels of expression were glycogenes from our target list. A chi-
square analysis revealed that the difference between the observed
change in glycogenes was not significant compared to the expected
value. These results do not suggest an enrichment of regulation of
glycan-related genes in characterizing differences between actively
migrating and stationary cells.
Fewer genes showed differential expression between the groups
than in the above models (Tables 6 and 7). Eight target genes
increased expression by more than 1.5-fold in both migrating
MiaPaCa-2 and Panc-1. No genes increased by more than two-
fold in both cell types. No clear themes in glycogene function were
discernable among the genes with increased expression. Nine
target genes decreased expression levels over 1.5 fold in both
Migrating MiaPaCa-2 and Panc-1. Two are related to the removal
of mannose in the biosynthesis of N-glycans, MAN1A2 and
MANBA. The mucin MUC12 was the only gene with decreased
expression greater than two-fold in both cell types.
Shared Genes and Functional Themes
We next investigated whether certain gene expression changes
were common between two or more of the model systems. Such an
analysis is useful to provide more guidance on which genes are
important in multiple aspects of EMT or are functionally
important in processes related to EMT. The overlap between
Table 3. Genes with decreased expression in TGFb-induced EMT.
Category Symbol Name
1 Entrez ID
EMT Induced Panc-1 Fold
Change
2
EMT Induced A549
Fold Change
2
Glycoproteins CDH1 cadherin 1, type 1, E-cadherin (epithelial) 999 4.01 9.52
Glycan-transferase ST8SIA4 ST8 alpha-N-acetyl-neuraminide alpha-2,8-
sialyltransferase 4
7903 2.96 8.16
CBP:C-Type Lectin KLRC3 killer cell lectin-like receptor subfamily C, member 3 3823 6.84 2.78
CBP:C-Type Lectin CD302 C-type lectin domain family 13, member A 9936 2.31 3.13
EMT Marker TWIST2 twist homolog 2 (Drosophila) 117581 2.66 2.27
Galectin LGALS3BP Galectin 6 binding protein 3959 1.91 2.78
1Only probes showing a greater than +/250% change in expression were included. Genes in bold show a common trend with the 22-cell line panel.
2The results were averaged when multiple probes for a given gene were present.
doi:10.1371/journal.pone.0013002.t003
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and the cell line panel, only three genes were common: ZEB1 and
SULF2 were up-regulated in both models, and CDH1 was
decreased in both. Using data only from the Panc-1 cell line in the
TGFb-induced and migrating cell models, ST6GALNAC4
increased and PIGM decreased in all model systems. These results
show that while glycogenes are altered in each model and are
particularly enriched in induced-EMT and the cell line panel, the
specific genes involved in each are divergent between the systems.
Although many of the altered genes were different between the
induced-EMT model and cell line panel, several functional themes
were present in both. The most predominant shared theme was
the modulation of the glycosaminoglycan (GAG) component of the
extracellular matrix. SPOCK1 and VCAN (versican) are both
matrix proteins bearing GAG chains, and both systems showed
up-regulation of genes that add and take away sulfate from those
chains, including SULF2, CHST3, CHST11, HAS2, CHST7,
SGSH, and NDST2. An Alcian Blue assay was conducted to
further characterize the overall sulfation levels between the
epithelial and mesenchymal-like cell lines as well as after induction
of EMT in Panc-1 by TGFb (Figure 4). A significant increase in
overall sulfation was seen for the mesenchymal-like cell lines
(p=1.29610
25). Inducing EMT in Panc-1 by TGFb continued
the trend of significantly increasing overall levels of sulfation
Figure 1. Morphologies and clustering of selected pancreatic cancer cell lines. Mesenchymal-like cell lines are presented in the top two
rows, and epithelial-like cell lines are in the bottom two rows. Note the increased cell scatter and spindle like projections seen in the mesenchymal-
like cells as compared to the tighter cell-cell adhesion and more spherical shape characteristic of the epithelial cells. The images were collected by
phase-contrast microscopy at 106magnification.
doi:10.1371/journal.pone.0013002.g001
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two model systems in which they were suggested by gene
expression.
Another theme in common between the induced-EMT model
and the cell line panel was alterations to lectin-like receptors of the
mannose receptor family. The four members of this family,
MRC1, MRC2, LY75, and CD302, are transmembrane endocytic
receptors with multiple carbohydrate-binding domains. MRC2
was upregulated and CD302 was down-regulated in the induced-
EMT model, and LY75 was down-regulated in the cell line panel.
The two EMT models also shared alterations to member of the N-
acetyl galactosamine (GalNAc) transferase family, which catalyze
the initial addition of GalNAc to a serine or threonine residue in
mucin-type O-linked glycosylation. GALNT2 and GALNT10
were up-regulated in induced EMT, and GALNT3 was the
strongest discriminator of epithelial-like and mesenchymal-like
cells in the cell line panel, with expression dropping below
measureable levels in the mesenchymal cells (Figure 4).
Validation of Gene Expression Differences
The differential gene expression in the mesenchymal-like and
epithelial-like cell lines was confirmed for certain genes using RT-
PCR and Western Blot (Figure 5). The correlations between the
RT-PCR and microarray results were generally consistent, with
the strongest correlations seen for GALNT3, 0.912; ZEB1, 0.774;
GMPPA, 0.735; and MAN2B2, 0.713; and weaker correlations for
ST3GAL6, 0.509; and PMM1, 0.415. Protein-level changes were
confirmed by Western Blot for GALNT3 and MRC2. GALNT3
detection was positive for the epithelial cell lines BXPC-3, HPAF
II, and SU86.86 while remaining undetected in the mesenchymal-
like cell lines MiaPaCa-2, MPanc-96, and Panc-1. MRC2 was
only detected in A549, Panc-1, and MiaPaCa-2 and showed
increased levels after treatment with TGFb in these three cell lines.
There was no detectable level of MRC2 for BXPC-3 or HS766t in
the presence or absence of TGFb.
Discussion
The ability to detect or control EMT in pancreatic cancer could
lead to improved treatment strategies. The characterization of
molecular alterations associated with EMT is a first step in
unraveling some of the mechanisms driving this process. Defining
the glycan changes associated with EMT may be especially
Figure 2. E-cadherin and vimentin protein levels in selected
pancreatic cancer cells. Lysates were collected from the selected cell
lines, fractionated by SDS-PAGE, and probed by Western blot. The
highlighted bands are at the expected molecular weights of 110 kD for
E-cadherin, 57 kD for vimentin, and 42 kD for actin.
doi:10.1371/journal.pone.0013002.g002
Table 4. Genes with higher expression in mesenchymal-like cell lines as compared to epithelial-like.
Category Symbol Name
1 Entrez ID p value
2 Fold Change
2
CBP:C-Type Lectin VCAN Versican 1462 2.81E-03 to 4.16E-03 20.75 to 39.03
EMT Marker ZEB1 zinc finger E-box binding homeobox 1 6935 1.55E-10 to 7.44E-08 4.98 to 11.72
Glycan Degradation SULF2 sulfatase 2 55959 3.92E-03 to 5.77E-03 7.56 to 8.26
EMT Marker VIM Vimentin 7431 4.61E-05 to 1.44E-03 7.38 to 7.55
Glycoproteins MUPCDH mucin and cadherin-like 53841 2.04E-03 7.14
Glycoproteins LAMA4 laminin, alpha 4 3910 2.85E-03 to 2.90E-03 3.70 to 3.87
Glycan-transferase CHST7 carbohydrate (N-acetylglucosamine 6-O) sulfotransferase 7 56548 2.61E-03 3.43
Glycan-transferase MGAT5B mannosyl (alpha-1,6-)-glycoprotein beta-1,6-N-acetyl-
glucosaminyltransferase, isozyme B
146664 1.16E-03 3.35
Glycan Degradation SMPD1 acid sphingomyelinase 6609 7.33E-04 2.97
Glycan Degradation CTSA cathepsin A precursor 5476 3.45E-03 2.39
Glycoproteins SELPLG selectin P ligand 6404 6.93E-03 2.24
Glycan Degradation SGSH N-sulfoglucosamine sulfohydrolase (sulfamidase) 6448 1.51E-04 2.10
Glycan-transferase ST3Gal2 ST3 beta-galactoside alpha-2,3-sialyltransferase 2 6483 3.12E-05 2.05
Glycan-transferase ST6GalNAc4 ST6 (alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl-1,3)-N-
acetylgalactosaminide alpha-2,6-sialyltransferase 4
27090 3.73E-03 to 8.64E-03 1.97 to 2.00
TGFa ˆ Pathway TIAF1 TGFB1-induced anti-apoptotic factor 1 9220 1.00E-02 1.93
Glycan Degradation GALNS N-acetylgalactosamine-6-sulfatase precursor 2588 4.85E-03 1.85
Glycan-transferase NDST2 N-deacetylase/N-sulfotransferase (heparan glucosaminyl) 2 8509 1.85E-04 1.81
Glycan-transferase POMGNT1 beta1,2-N-acetylglucosaminyltransferase 55624 3.70E-03 1.78
Glycan-transferase POFUT1 protein O-fucosyltransferase 1 23509 4.00E-03 1.70
Glycan Degradation GBA glucosidase, beta; acid 2629 2.82E-03 1.70
Glycan-transferase B3GNT1 UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 1 11041 9.61E-03 1.64
doi:10.1371/journal.pone.0013002.t004
Glycogenes in EMT
PLoS ONE | www.plosone.org 6 September 2010 | Volume 5 | Issue 9 | e13002important for understanding this process, given the known
involvement of glycans in other cell differentiation processes.
Whole-genome expression profiling combined with a target gene
list of 587 glycosylation-related genes was a practical means of
investigating glycosylation in this biological system. In addition,
the use of three in-vitro model systems proved useful for examining
complementary aspects of the epithelial and mesenchymal states,
namely the active transition between states, the terminal
differentiation states, and the act of migration.
The importance of glycan alterations in EMT was supported by
thefrequency ofchanges to glycosylation-associated genes(Table1).
Glycan-associated genes were altered more frequently than was
predictedintwoofthemodelsystems,TGFb-inducedEMTandthe
cell line panels, butnot in the cell migration model. The finding that
glycan remodeling is a major aspect of the cell differentiation
process would be consistent with previous work showing the
importance of glycan alterations in stem cell biology and immune
activation [27,31,37]. The lack of major glycogene changes in cell
migration between may indicate that the migrating cells were not
actually differentiating, but rather just altering expression for the
mechanics of migration. Therefore glycan changes may be more
important as indicators of cell type and status rather than as
functional contributors to migration. However, it should be noted
that alteration of glycosyltransferase activity in cell line models have
shown differential effects on migratory ability in vitro [38,39,40]. In
the case of Panc-1 and MiaPaCa-2, they may already possess the
glycan-machinery necessary for an enhanced migratory ability;
further transformation may not be necessary. This area of the
investigation was also limited to two pancreatic cancer cell lines in
very specific in vitro conditions. Future analyses using more cell lines
and different methods of separating migratory from stationary cells
may yield new findings.
The functional themes shared by the induced EMT model and
the cell line panel give some insights into the roles of glycosylation
in EMT. The alterations of proteoglycans and sulfation enzymes
suggest the importance of the control of GAG sulfation in EMT.
This finding is consistent with previous research showing
alterations to matrix components such as versican [41] and
alterations to GAG sulfation [42] in association with cancer,
particularly in aggressive forms of cancer. The cancer-promoting
functions of versican may act through regulating growth factor
activity and by interacting with immune and stromal cells [43],
functions which could be modified by alterations to sulfation.
SPOCK1 may function through similar mechanisms but is less
well studied. SULF2, which was strongly up-regulated in both
systems and acts to remove sulfates from certain GAG chains, also
has been associated with lung carcinogenesis [44] and the
tumorigenicity of pancreatic cancer cells [45]. The cancer-
promoting functions of SULF2 appear to work through activating
Wnt signaling or releasing growth factors from the extracellular
matrix, which may also have a pro-angiogenic effect. The
association of these functions with cancer EMT suggests that
cancer cells undergoing EMT use a reconditioning of the
extracellular space to become highly invasive. If so, interfering
with GAG sulfation and desulfation, or the interactions induced by
modified sulfation, represent attractive targets for intervention,
particularly since these molecules reside in the extracellular space.
The evaluation of total sulation levels using Alcian Blue staining
revealed an increase in overall sulfation for the mesenchymal-like
cell lines as well as an increase in Panc-1 sulfation after treatment
with TGFb. This effect could be due to an increase in GAG-
bearing proteins such as SPOCK1 or VCAN, as seen in the
induced EMT and mesenchymal-like cell line panel, respectively.
Another possibility is increased sulfate on each GAG chain, which
could be induced by increased sulfotransferase levels. We observed
higher levels of CHST3 & CHST11 in the induced EMT model
and higher CHST7 & NDST2 in the mesenchymal-like cell panel.
These pro-sulfation activities must outweigh the effects of the
increased SULF2 sulfatase, which removes sulfates. Since SULF2
is specific for heparin and heparan sulfate [46], and CHST3,
CHST11, and CHST7 act on chondroitin sulfate, an interesting
possibility is a shift in sulfation from heparan sulfate to chondroitin
sulfate. Further researh will address the nature of the increased
sulfation levels as well as the biological effects of these alterations.
The alterations in mannose receptor family members could have
implications for cellular interactions with a reconditioned local
environment. Mannose receptor family members have specificity
for various matrix components such as collagen and sulfation [47].
Collagen wasup-regulatedinthe mediaof both A549 and Panc-1as
determined by mass-spectrometry profiling (data not shown), and
multiple other matrix components are altered by cancer cells, as
discussed above. Considering these factors, altered regulation of
mannose receptors suchas MRC2 could be a means to conditioning
the cellular response to the new matrix environment or acting to
mediate autocrine loops. In addition, MRC2 is involved in
chemotaxis and invasion [48] and could be important for the
acquisition of those traits by cancer cells.
UDP-N-acetyl-d-galactosamine: polypeptide UDP-N-acetylga-
lactosaminyltransferases (GALNTs) initiate O-glycosylation by
attaching a GalNAc to a serine or threonine on target proteins.
There are currently 15 reported isozymes in the GALNT family
with variations in substrate specificity [20]. Many of the GALNTs
Table 5. Genes with lower expression in mesenchymal-like cell lines as compared to epithelial-like.
Category Symbol Name
1 Entrez ID p value
2 Fold Change
2
Glycan-transferase GALNT3 polypeptide N-acetylgalactosaminyltransferase 3 2591 2.17E-04 1116.29
CBP:C-Type Lectin LY75 lymphocyte antigen 75 4065 7.06E-03 22.82
Glycoproteins MUC4 Mucin 4, cell surface associated 4585 8.31E-03 11.55
Glycoproteins CDH3 cadherin 3, P-cadherin (placental) 1001 4.49E-03 7.98
Glycoproteins CDH1 cadherin 1, type 1, E-cadherin (epithelial) 999 9.91E-04 to 9.74E-03 3.38 to 5.78
CBP:C-Type Lectin CLEC3A C-type lectin domain family 3 member A 10143 2.21E-03 4.76
Glycan-transferase PIGM phosphatidylinositol glycan anchor biosynthesis 93183 7.42E-03 1.57
1Only genes showing a significant change (p#0.01) and greater than +/250% change in expression were included. Genes in bold show a common trend with the EMT
induced cancer cell lines.
2Genes represented by multiple probes have p values and fold changes represented as ranges.
doi:10.1371/journal.pone.0013002.t005
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restricted tissue expression [49,50]. This diversity allows variation
in the glycoforms of various proteins depending upon cell origin
and cell state [51]. Alterations to O-glycan initiation through
modulation of the GALNTs, particularly GALNT3, may also
affect cancer cell behavior by changing the glycoform of target
protein(s) and thereby altering interactions with the cellular
environment. Notably, GALNT3 expression is restricted to
glandular epithelial cells in normal tissue [49] and adenocarcino-
mas [52]. Consistent with our observations here, loss of GALNT3
previously has been associated with the mesenchymal phenotype
[51] as well as with a poorer cancer prognosis [52,53,54]. The
identification of the particular proteins acted upon by GALNT3
will be a future research goal.
The genes that were common between the model systems may be
of particular interest for further study. Changes in the expression of
ST6GALNAC4 were shared between all pancreatic cell experi-
ments (excluding the A549 lung cancer cell line). ST6GALNAC4
catalyzes the addition of sialic acid (Neu5Ac) to the 69 carbon of N-
acetylgalactosamine (GalNAc) of the acceptor motif Neu5Ac-alpha-
2,3-Gal-beta-1,3-GalNAc on glycoproteins and glycolipids, result-
ing in a terminal, di-sialylated glycan structures [20]. It was
noteworthy that a functionally-related gene, ST3GAL2, was also
up-regulated in the mesenchymal-like cells of the cell line panel.
ST3GAL2 catalyzes the addition of Neu5Ac in alpha 2,3 linkage to
galactose in the acceptor motif Gal-beta-1,3-GalNAc [20,55],
potentially forming the acceptor motif for ST6GALNAC4.
Cancer-associated glycans have been shown to have increased
sialylation, resulting in increased metastatic potential [50,56] and
tumor growth [57]. An unexpected result was seen in the induced
EMT model for a sialyltransferase: ST8 alpha-N-acetyl-neurami-
nide alpha-2,8-sialyltransferase 4 (ST8SIA4). This enzyme is one of
several family members capable of forming polysialic acid (PSA), a
known modulator of neural cell adhesion via the neural cell
adhesionmolecule(NCAM)[58].Investigations into the roleofPSA
in pancreatic cancer has shown that PSA-NCAM represses E-
cadherin mediated cell-cell adhesion and that removal of PSA
results in increased cell aggregation and reduced migration [59].
Loss of ST8SIA4 would then be expected to favor a decrease in
migration. However, it should also be noted that NCAM was not
detected in our study at the transcript level (data not shown).
The second gene expression change shared between all
pancreatic experiments was down-regulation of PIGM (phospha-
tidylinositol glycan anchor biosynthesis, class M). PIGM catalyzes
the initial mannosylation in the formation of glycosylphosphati-
dylinositol (GPI) membrane anchors. GPIs are glycolipids that are
involved anchorage dependent tethering of many cell surface
proteins [60]. Decreased expression of PIGM due to promoter
mutation has been shown to cause severe GPI anchor deficiency
[61]. A decrease in PIGM levels due to downregulation of the gene
might also lead to a decreased prevalence of GPI anchored
proteins at the cell surface.
These insights into the genes and glycosylation patterns that are
associated with the development and maintenance of mesenchy-
mal-like pancreatic cancer cells can be applied to future studies in
a variety of ways. Future work to characterize the structures of the
glycans using mass spectrometry should be compared to these gene
expression results to piece together the links between the
biosynthetic pathways and the most prevalent glycan alterations
in EMT. If these molecular alterations prove to be highly selective
to mesenchymal-like cancer cells, therapeutic strategies based on
this information may be highly effective to particularly target the
cells most involved in cancer progression and drug resistance.
Methods to selectively modulate glycosylation or protein-glycan
interactions at key points have been investigated for inflammation,
metastasis, and pathogen invasion [62,63,64,65]. The information
from this study also may be useful to develop biomarkers to detect
mesenchymal-like cancer cells. We previously showed that
measuring glycans on specific proteins can produce improved
biomarker performance over just measuring protein abundances,
due to the fact that both protein abundance and glycosylation can
be altered in cancer [66,67]. Future studies will aim to identify the
proteins that enzymes identified here act upon, so that the
glycosylation levels on those proteins can be efficiently probed
using antibody-lectin sandwich arrays (ALSA) [66,67]. Using high-
throughput antibody array methods developed earlier, we can
rapidly characterize the associations between various glycoforms
and clinical states.
Figure 3. Expression patterns of genes discriminating the cell
lines. Genes were included that had significantly different (p,0.01)
expression levels between the mesenchymal-like (column labels colored
red) and the epithelial-like (column labels colored black) cell lines. The
expression values were log transformed (base 10) and median centered
by row. The value of each square is indicated by the color bar.
doi:10.1371/journal.pone.0013002.g003
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alterations in cancer EMT and supports the concept of the
importance of glycans in both the transition to and the
maintenance of the mesenchymal state. Alterations to matrix
components, the sulfation of GAGs, mannose receptors, O-
glycosylation, and specific sialylated structures characterize
pancreatic cancer EMT. The specific genes controlling these
modifications may be targets to prevent or reverse EMT, and the
glycan structures produced by these genes, coupled with the
proteins on which they are found, may provide molecular hooks to
specifically detect mesenchymal-like cancer cells. Glycan structural
analyses will provide further details about the activities of these
genes. These findings provide specific leads for future research into
the detection and targeting of particularly aggressive or drug-
resistant forms of pancreatic cancer cells.
Materials and Methods
Cell Culture and RNA Extraction
The cell lines used in the TGFb induced EMT and migration
models were purchased from the American Type Culture
Collection (ATCC, Manassas, VA). The 22 cell lines used in the
pancreatic cancer cell line panel were generously provided by
Drs. Martin McMahan and Stephan Gysin (University of
California San Francisco). All cells were grown according to
the ATCC recommended culture conditions for each cell line.
For the induced EMT model, Panc-1 and A549 were grown to
70% confluency, cultured for one day in serum-free conditions,
and incubated for 48 hours with fresh media containing either
5n MT G F b (R&D Systems), or plain media. The cells were
rinsed three times in 16phosphate-buffered saline prior to lysis
by the addition of TRIzol reagent (Invitrogen, Carlsbad, CA)
followed by repeated passes through an 18-G needle and a
5 min incubation at RT. The lysates were vigorously mixed with
chloroform and spun down at 120006gf o r2 0m i n u t e sa t4 uC.
The aqueous layers were transferred to an isopropanol solution,
mixed vigorously, and centrifuged at 120006g for 30 minutes at
4uC. The RNA-containing pellet was washed with 75% ethanol,
dried, and dissolved in RNase-free water. The RNA quantity
and quality was determined using a spectrophotometer (Bio-
photometer, Eppendorf, Westbury, NY) and stored at 220uC
until all cell lines were ready for cDNA synthesis and
polymerase chain reaction (PCR).F o rt h ec e l ll i n ep a n e lm o d e l ,
all cells were grown to 70% confluency under normal culture
conditions prior to lysis and RNA extraction using the above
protocol.
Table 6. Genes with higher expression in cell migration.
Category Symbol Name
1 Entrez ID
Panc-1 Migrate Fold
Change
2
MiaPaCa-2 Migrate
Fold Change
2
Glycan-transferase Gal3ST3 galactose-3-O-sulfotransferase 3 89792 3.88 1.54
Notch Pathway Notch4 Notch homolog 4 4855 2.93 1.83
Glycan-transferase FUT4 fucosyltransferase 4 (alpha (1,3) fucosyltransferase, myeloid-
specific)
2526 1.80 2.12
Glycan-transferase GALNT13 ppGalNAc T13; UDP-N-acetyl-alpha-D-galactosamine:
polypeptide
114805 2.28 1.61
Glycoproteins MCOLN1 mucolipin 1 57192 1.80 1.84
Glycoproteins CDH15 cadherin 15, type 1, M-cadherin (myotubule) 1013 1.68 1.93
Glycoproteins ITGA2 integrin, alpha 2 (CD49B, alpha 2 subunit of VLA-2 receptor) 3673 1.94 1.50
CBP:C-Type Lectin REG4 regenerating islet-derived family, member 4 83998 1.51 1.64
doi:10.1371/journal.pone.0013002.t006
Table 7. Genes with lower expression in cell migration.
Category Symbol Name
1 Entrez ID
Panc-1 Migrate Fold
Change
2
MiaPaCa-2 Migrate
Fold Change
2
Glycoproteins MUC12 mucin 12, cell surface associated 10071 2.31 3.45
Glycan Degradation MAN1A2 mannosidase alpha class 1A member 2 10905 1.89 2.59
TGFb Pathway TGFBR3 transforming growth factor, beta receptor III 7049 1.79 2.50
Nuc. Sugar SLC35A3 solute carrier family 35 (UDP-N-acetylglucosamine (UDP-
GlcNAc) transporter), member A3
23443 1.88 2.33
Glycan Degradation GALC galactosylceramidase precursor 2581 1.53 1.92
Glycan-transferase CHST1 carbohydrate (keratan sulfate Gal-6) sulfotransferase 1 8534 1.83 1.59
CBP:C-Type Lectin ATRN Attractin 8455 1.59 1.82
Glycan Degradation MANBA mannosidase, beta A, lysosomal 4126 1.57 1.56
CBP:C-Type Lectin REG3A Pancreatitis-associated protein 5068 1.54 1.54
1Only probes showing a greater than +/250% change in expression for both cell lines were included.
2Genes represented by more than one probe are represented as averages.
doi:10.1371/journal.pone.0013002.t007
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previously [68]. Isolation of sub-populations of stationary and
migratory cells were performed as described previously [36].
Briefly, to simulate a migratory front (rim) and proliferating core,
five thousand pancreatic cells were seeded as a confluent, circular
monolayer using cell sedimentation manifolds (CSM, Inc.,
Phoenix, AZ) on Collagen IV-coated, 10-well slides. Migration
was initiated by removing the manifolds 16 hours after seeding,
and the cells were allowed to radially disperse for 24 hours.
Stationary (core) and migratory (rim) cells were harvested under
an inverse microscope (Axiovert 100, Zeiss, NY) using a P20
pipette in four independent biological replicates. Forty individual
dispersion assays (four 10-well slides) were collected and
immediately isolated for RNA according to manufacturer’s
protocol (Mirvana Total RNA Kit, Ambion, Austin, TX). Core
and rim cells were separately lysed with Lysis Binding Buffer.
Total RNA quantity was assessed using a NanoDrop 2000c
(Thermo Scientific, Wilmington, DE), and quality was assessed by
Bioanalyzer RNA 6000 Nano LabChip Kit (Agilent Technologies,
Palo Alto, CA).
Microarray Data Collection and Analysis
All microarray data are compliant with the MIAME standards
and are deposited in the GEO database. The accession numbers
are GSE17708for the A549 cell line data; GSE21654 for the cell
line panel; and GSE21566 for the migrating cell model. The
induced-EMT and the cell line panel models were analyzed on the
Affymetrix Human Genome U133 Plus 2.0 chip at the University
of Michigan and the Van Andel Institute, respectively.
The resulting gene expression data from all model systems were
analyzed using Microsoft Excel and Xenobase (26). A list of 587
genes of interest (see Table S1) was assembled using information
from the Consortium for Functional Glycomics in addition to
project-specific information. These genes include glycan-transfer-
ases (199 genes), glycoproteins (101 genes), lectins (112 genes),
glycosidases (62 genes), nucleo-sugar transport (35 genes), nucleo-
sugar synthesis (23 genes), golgi transport (8 genes), TGF pathway
(19 genes), notch pathway (18 genes), and EMT markers (10
genes). 96.7% of these genes are represented on the Affymetrix
Human Genome U133 Plus 2.0, and 92.2% are represented on
the Agilent Whole Human Genome Microarray Kit, 4644K. A
Chi-square test was used to determine whether gene expression
changes within this list occurred more frequently than all other
changes.
For the analysis of TGFb–induced EMT of PANC-1, a paired,
two-tailed, t-test was performed between the triplicate experiments
of each condition, with a p value less then 0.05 considered
significant. Probes with mean absolute signal levels below 100 for
both conditions were excluded. Analysis of TGFb treated A549
used the pairwise ratios in transcript levels between the 0 hour and
72 hour time points. For the analysis of the 22 cell line panel, an
unpaired, two-tailed, t-test was applied with a p value less than
0.01 considered significant. For the analysis of migrating Panc-1
and migrating MiaPaCa-2 cell lines, probes were excluded that
showed less than a 625% change in expression from rim to core,
and genes were excluded that had multiple probes respectively
showing both positive and negative changes. The results from the
remaining probes were averaged for each gene. The data discussed
in this publication have been deposited in NCBI’s Gene
Expression Omnibus and are accessible through GEO series
expression numbers: GSE17708 & GSE23952 (A549 & Panc-1
TGFb treatment assay, respectively), GSE21654 (22 Pancreatic
Cancer Cell Line Panel), GSE21566 (Radial Migration Assay).
Gene Expression Validation by RT-PCR
Synthesis of the first strand cDNA template closely followed the
outlined protocol for the use of SuperScript II Reverse
Transcriptase (Invitrogen, Carlsbad, CA). cDNAs were synthe-
sized in a 20 ml reaction at RT. The first step used 5 mg RNA,
random hexamer , dNTP mix, and ddH2O to a final volume of
12.5 ml incubated at 65uC for 5 minutes then quick chilled on ice.
Once chilled, 56first strand buffer stock, RNase inhibitor, DTT,
and SuperScript II RT were added and incubated at RT for
Figure 4. RT-PCR and Western blot verification of microarray
data for selected pancreatic cancer cell lines. (A) RT-PCR was
performed on lysates from the indicated cell lines, and intensities of the
bands at the expected size for each gene were quantified. A student’s t-
test (results given by the p value) was performed comparing the band
intensities between the mesenchymal-like cell lines (in bold) and the
epithelial cell lines. In addition, a correlation was calculated (results
given by the r value) between the RT-PCR results and the microarray
data. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used
as a cDNA loading control. (B) Comparison of GALNT3 protein levels by
Western blot in selected pancreatic cancer cell lines. Lysates were
collected from the selected cell lines, fractionated by SDS-PAGE, and
probed by Western blot. Mesenchymal-like cell are labeled in bold. The
highlighted bands are at the expected molecular weights of 73 kD for
GALNT3 and 42 kD for actin. (C) MRC2 protein levels measured by
Western blot in TGFb treated and untreated cells. The cell lines were
either exposed to 5 ng/mL TGFb or untreated under serum starvation
for 72 hours prior to cell lysis. The highlighted bands are at the
expected molecular weights of ,167 kD for MRC2 and 42 kD for actin.
doi:10.1371/journal.pone.0013002.g004
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out at 42uC for 1 hour and subsequently inactivated at 70uC for
10 minutes.
Gene-specific primers corresponding to selected genes from the
Affymetrix U133 Plus 2.0 chip were designed using MacVector
(MacVector Inc., Cary, NC) and synthesized (Integrated DNA
Technologies, Inc., Coralville, IA). The following sequences were
used. GALNT3: EX-S: 59-ACAGTGTGCTCTATTCTTCA-
CCTGC-39. EX-AS: 59-TTACGACAGCCGTGTAGTTCTCA-
G-39. ST3GAL2: EX-S: 59-CCTGCTGGTGTTCATCATGT-
CC-39. EX-AS: 59-GCACCTCATTGGTGTTGTGTGAC-39.
ST3GAL6: EX-S: 59-CAGCTTTTGCCTCTCTGCTGAG-39.
EX-AS: 59-TCTCCCAACTTCTTCTTCATGTCC-39. PMM1:
EX-S: 59-CAAGCAGACCATCCAGAACCAC-39. EX-AS: 59-
AGAGAACCTCAGCCCTTTGCCAG-39. MAN2B2: EX-S:
59-CCTAAACAGCCAGCAGGTCATC-39. EX-AS: 59-TGTC-
GTTCAGCGTGAGGTTGTAG-39. GMPPA: EX-S: 59-TCC-
TTGGCACTACGGCTAACAG-39. EX-AS: 59-GGGCTGAA-
AACACATCCTGCTC-39. ZEB1: EX-S: 59-AATCCCAC-
CAAGTGCCAACC-39. EX-AS: 59-CATTCCATTTTCTGT-
CTTCCGC-39. The Tm of these primers ranged from 54.5 to
61.5uC as reported by the manufacturer.
Each 50 ml reaction tube contained 0.5 mg cDNA template,
4mM primers, and the Qiagen reagents 16 PCR buffer, 16 Q
solution, 0.2 mM dNTPs, and HotStar Taq DNA polymerase.
The amplification program consisted of one activation round of
95uC for 15 minutes followed by 25 cycles of 94uC with a
50 second hold, 55uC with a 1 minute hold, and 72uC with a
50 second hold. The reaction was allowed to continue at 72uC for
10 minutes and held at 4uC. The PCR products were analyzed
using a 1.5% agarose gel in 16 Tris base, acetic acid and
ethylenediaminetetraacetic acid (EDTA) buffer (TAE). The gel
bands were imaged and analyzed using the software programs
Chemidoc and Quantity One (Bio-Rad, Hercules, CA).
Western Blots
Cells were lysed in Radio-Immunoprecipitation Assay (RIPA)
buffer containing protease inhibitor (Roche). The solution was
centrifuged to remove the pellet. The protein-containing super-
natant was then quantified using the microBCA assay (Thermo
Scientific) and adjusted to equivalent concentrations prior to
loading on 4–12% polyacrylamide gels (Criterion, BIO-RAD).
The proteins from the gel were electrophoretically transferred to
Polyvinylidene Fluoride (PVDF) membrane, which was blocked in
5% milk and incubated with primary antibody overnight at 4uC.
After washing with Tris-Buffered Saline containing 0.5% Tween
20 thrice for 10 minutes each, the membrance was incubated with
horseradish peroxidase (HRP)-conjugated secondary antibody for
1 hour and washed again. The membrane was incubated with
substrate (SuperSignal West Pico, Thermo Scientific) for 5 min-
utes and visualized using BIO-RAD ChemiDOC XRS. The
primary antibodies targeted E-cadherin (R&D Systems, mAb
Figure 5. Alcian Blue assay for comparison of overall sulfation levels for selected pancreatic cancer cell lines. An Alcian Blue assay was
performed on lysates from the indicated cell lines, and the overall sulfation for each cell line was quantified by measuring the absorbance of the dye
at 600 nm. A student’s t-test (results given by the p value) was performed comparing the absorbances between the mesenchymal-like cell lines (in
bold) and epithelial cell lines as well as between Panc-1 after 72 hours of TGFb treatment and untreated Panc-1. Heparin was used as a sulfated GAG
control. (A) Photograph of the resulting retention of Alcian Blue dye after the precipitation of sulfated glycans and subsequent re-suspension. The
second column represents the mesenchymal-like cell lines and retained more stain, indicating the presence of higher levels of sulfated glycans in the
cell lysates. (B) Bar graphs showing the differences in absorbance at 600 nm for the cell lines. The mesenchymal-like cell lines (in bold) had
significantly higher levels of absorbance than the remaining epithelial cell lines (p=1.29610
25). (C) Bar graphs showing the differences in absorbance
at 600 nm for Panc-1 after 72 hours exposure to 5 ng/mL TGFb or untreated under serum starvation. Panc-1 after TGFb treatment had significantly
higher levels of absorbance than the untreated Panc-1 (p=0.027).
doi:10.1371/journal.pone.0013002.g005
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ab70132), and Actin (1–19) (Santa Cruz, SC-1616). The GALNT3
antibody was produced and generously donated by the laboratory
of Dr. Henrik Clausen [51,69].
Sulfated Glycosaminoglycan Assay
The Alcian Blue Assay closely followed a previously established
protocol [70] with minor alterations. Cells were lysed in Radio-
Immunoprecipitation Assay (RIPA) buffer containing protease
inhibitor (Roche). The solution was centrifuged to remove the
pellet. The protein-containing supernatant was then quantified
using the microBCA assay (Thermo Scientific) and adjusted to
equivalent concentrations prior to analysis. All of the following
reagents were purchased from Sigma, Samples were initially
denatured in 3.3 M urea, 0.1% H2SO4, and 0.25% octylphenox-
ypolyethoxyethanol (Triton X-114) for 30 minutes at room
temperature. Alcian Blue stain solution (0.07% Alcian Blue/
0.1% H2SO4/0.25% Triton X-114) was then added to give final
concentrations of 0.05% Alcian Blue, 0.56 M urea, 0.1% H2SO4,
and 0.25% Triton X-114. Samples were then left at 4uC overnight
to allow precipitation of Alcian Blue bound species. The
concentration of H2SO4 used should give a pH between 1.5 and
2.0 to allow for the majority of species carrying negative charge to
be sulfate residues for specific binding by the cationic dye. The
next day the samples were centrifuged at 12,0006g for 15 minutes
and the supernatant containing unbound dye was discarded. The
pellets containing the dye bound molecules were re-suspended in
1 mL of a solution of 40% dimethylsulfoxide (DMSO) and 0.07M
MgCl2 then centrifuged at 12,0006g for 15 minutes and the
supernatant was once again discarded. The remaining pellet was
re-dissolved in 500 mL of a solution of 5M urea, 33% 1-propanol,
and 0.25% Triton X-114 to measure absorbance. Measurements
for absorbance at 600 nm were performed in triplicate using a
BioPhotometer (Eppendorf). A solution of 5M urea, 33% 1-
propanol, and 0.25% Triton X-114 was used as a blank. Heparin
(H3393, Sigma) was used as a positive control. The statistical
analyses and graphing were performed in Microsoft Excel.
Supporting Information
Table S1 A list of 587 genes of interest was assembled using
information from the Consortium for Functional Glycomics in
addition to project-specific information. These genes include
glycan-transferases (199 genes), glycoproteins (101 genes), lectins
(112 genes), glycosidases (62 genes), nucleo-sugar transport (35
genes), nucleo-sugar synthesis (23 genes), golgi transport (8 genes),
TGF pathway (19 genes), notch pathway (18 genes), and EMT
markers (10 genes).
Found at: doi:10.1371/journal.pone.0013002.s001 (0.06 MB
XLSX)
Figure S1 TGFb-induced EMT in PANC-1. PANC1 cells were
cultured in serum-free media for 24 hours followed by treatment
with (A) control media or (B) 5 nM TGFb. The photomicrographs
were taken after 72 hours at 106magnification.
Found at: doi:10.1371/journal.pone.0013002.s002 (1.13 MB TIF)
Figure S2 Expression profiles of EMT-associated genes in the
panel of pancreatic cancer cell lines. The cells lines were grouped
according to morphological characteristics. The expression level of
each gene was log transformed (base 10) and median centered by
row. The value of each square corresponds to the color bar at top.
The levels of the ZEB1 gene most clearly associated with
morphology.
Found at: doi:10.1371/journal.pone.0013002.s003 (0.47 MB TIF)
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